XGN
Exagen Inc.
XGN lost money over the past year, so it has no meaningful PE right now. Analysts expect losses to shrink.
XGN Fundamentals
| Metric | Status |
|---|---|
| Healthy | |
| Under pressure | |
| Weak | |
| Unavailable |
XGN's revenue is currently healthy, but its profitability and cash flow are under pressure. There isn't enough data to rate its balance sheet.
XGN PE Valuation
XGN has no meaningful PE right now: it lost money over the past year.
XGN Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Losses shrinking | |
| Growth | |
| Strongly improving | |
| Limited | |
| Moderate |
Analysts expect XGN's losses to shrink, with revenue growing.
XGN Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q3 2026 | -$0.76 | +$0.16 |
| Q2 2026 | -$0.82 | +$0.07 |
| Q1 2026 | -$0.90 | -$0.06 |
| Q4 2025 | -$0.93 | -$0.10 |
| Q3 2025 | -$0.92 | +$0.02 |
| Q2 2025 | -$0.89 | +$0.08 |
| Q1 2025 | -$0.84 | +$0.25 |
| Q4 2024 | -$0.83 | +$0.51 |
XGN is still losing money, but far less than before: $0.76 per share over the past year, against $2.77 at its worst in late 2022.
XGN Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $18.4M | +6.8% |
| Q2 2026 | $19.9M | +16% |
| Q1 2026 | $17.3M | +12% |
| Q4 2025 | $16.6M | +22% |
| Q3 2025 | $17.2M | +38% |
| Q2 2025 | $17.2M | +14% |
| Q1 2025 | $15.5M | +7.5% |
| Q4 2024 | $13.7M | -0.8% |
XGN's revenue has grown year over year for seven quarters in a row: $18M last quarter, up 6.8% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | -24% | -5.9 points |
| Q2 2026 | -8.6% | +6.6 points |
| Q1 2026 | -20% | +2 points |
| Q4 2025 | -30% | -5.1 points |
| Q3 2025 | -18% | +19 points |
| Q2 2025 | -15% | +1.9 points |
| Q1 2025 | -22% | -0.9 points |
| Q4 2024 | -25% | +13 points |
XGN's operating margin was −24% last quarter, down 5.9 points from the same quarter a year ago.
XGN Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | -$2.8M | -204% |
| Q2 2026 | $3.4M | +$6.5M |
| Q1 2026 | -$10.6M | +$139K |
| Q4 2025 | -$3.1M | -1509% |
| Q3 2025 | $2.7M | +$5M |
| Q2 2025 | -$3.1M | -$532K |
| Q1 2025 | -$10.8M | -$1.7M |
| Q4 2024 | $217K | -97% |
XGN has burned cash in almost every quarter: −$13M over the past year, against −$11M the year before.
XGN Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +2.8% | +685K shares |
| 1 year | +8.3% | +1.9M shares |
| 3 years | +40% | +7.2M shares |
| 5 years | +47% | +7.9M shares |
| Available history | +97% | +12.3M shares |
XGN has 25M diluted shares, up 8.3% from a year ago.
XGN Net Leverage
XGN's operating earnings (EBITDA) were negative over the past year, so its debt can't be measured against them.
XGN Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 40.3 | Neutral |
| Stochastic | 38.4 | Neutral |
XGN's weekly RSI is 40 (neutral) and its Stochastic is 38 (neutral).
XGN PE vs Healthcare Sector
XGN has no meaningful PE right now: it lost money over the past year.
XGN Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $7.39 | 40% below |
| 20 week MA | $6.68 | 34% below |
| 50 week MA | $5.21 | 15% below |
| 100 week MA | $6.05 | 27% below |
| 200 week MA | $4.23 | 4.3% above |
XGN has fallen below most of its moving averages, though it's still 4.3% above its 200-week average.
XGN Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $25.7 | $12.3 | -52% |
| 2021 | $12.3 | $11.0 | -10% |
| 2022 | $11.0 | $2.45 | -78% |
| 2023 | $2.45 | $1.99 | -19% |
| 2024 | $1.99 | $4.71 | +137% |
| 2025 | $4.71 | $6.13 | +30% |
| 2026 YTD | $6.13 | $4.41 | -28% |
XGN's yearly returns have swung widely, from +137% in 2024 to −78% in 2022. It's down 28% so far in 2026.